|Bid||43.55 x 1200|
|Ask||45.78 x 900|
|Day's range||45.60 - 47.32|
|52-week range||31.36 - 48.58|
|Beta (5Y monthly)||1.23|
|PE ratio (TTM)||15.27|
|Earnings date||08 Aug 2022 - 12 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||49.71|
Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs developed using ENHANZE. Robust revenue growth is expected to continue in 2022.
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the Goldman Sachs 43rd Annual Global Healthcare Conference being held in Rancho Palos Verdes, CA on June 14-16, 2022.